| pubmed-article:10995013 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C1332710 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C1552913 | lld:lifeskim |
| pubmed-article:10995013 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:10995013 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:10995013 | pubmed:dateCreated | 2000-10-6 | lld:pubmed |
| pubmed-article:10995013 | pubmed:abstractText | We compared the biological effects of the CXC chemokine SDF-1alpha on immunomagnetically purified CD34+ cells isolated from human normal bone marrow (NBM), leukapheresis products (LP) and patients with chronic myeloid leukaemia (CML). LP CD34+ cells showed a significantly stronger migration response to SDF-1alpha (100 ng/ml) than CD34+ cells isolated from the peripheral blood (PB) of CML patients (P < 0.05). The chemotactic response to SDF-1alpha was also reduced in CML BM CD34+ cells in comparison to NBM CD34+ cells but the observed differences were not statistically significant. In analogy to normal CD34+ cells circulating CML PB CD34+ cells were less responsive to SDF-1alpha than their BM counterparts (P < 0.05). Furthermore, SDF-1alpha elicited similar concentration-dependent growth suppressive effects on normal and CML CD34+ cells (P > 0.05) in colony-forming cell assays. We then demonstrated that SDF-1alpha triggers intracellular calcium increases in CD34+ cells and there were no differences in the time course and dose response characteristics of normal and CML CD34+ cells. The reduced migration response to SDF-1alpha in CML CD34+ cells was not due to a down-regulation of the SDF-1alpha receptor CXCR-4 as flow cytometric analysis revealed similar CXCR-4 expression levels on NBM, LP, CML PB and CML BM CD34+ cells (P > 0.05). Finally, no differences in the modulation of CXCR-4 levels in response to SDF-1alpha and serum were observed in CML and normal CD34+ cells. Our data suggest that the impaired chemotactic response of CML CD34+ cells to SDF-1alpha is not caused by a lack or complete uncoupling of CXCR-4, but may be due to an intracellular signalling defect downstream of the receptor. | lld:pubmed |
| pubmed-article:10995013 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10995013 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10995013 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10995013 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10995013 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:RosenthalCC | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:DührsenUU | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:NovotnyJJ | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:KasperCC | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:HeyworthCC | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:DürigJJ | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:ElmaagacliAA | lld:pubmed |
| pubmed-article:10995013 | pubmed:author | pubmed-author:HalfmeyerKK | lld:pubmed |
| pubmed-article:10995013 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10995013 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:10995013 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10995013 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10995013 | pubmed:pagination | 1652-60 | lld:pubmed |
| pubmed-article:10995013 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:meshHeading | pubmed-meshheading:10995013... | lld:pubmed |
| pubmed-article:10995013 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10995013 | pubmed:articleTitle | Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells. | lld:pubmed |
| pubmed-article:10995013 | pubmed:affiliation | Department of Haematology, University Hospital Essen, Germany. | lld:pubmed |
| pubmed-article:10995013 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10995013 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10995013 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10995013 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10995013 | lld:pubmed |
